Results 61 to 70 of about 339 (90)

Levosimendan and Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials. [PDF]

Arq Bras Cardiol
Wan H, Feng J, Ji P, Chen W, Zhang J.
europepmc   +1 more source

The Efficacy and Safety of Levosimendan in Patients with Advanced Heart Failure: An Updated Meta-Analysis of Randomized Controlled Trials. [PDF]

Am J Cardiovasc Drugs
Elsaeidy AS, Abuelazm M, Ghaly R, Soliman Y, Amin AM, El-Gohary M, Elshenawy S, Seri AR, Abdelazeem B, Patel B, Bianco C.   +10 more
europepmc   +1 more source

Effect of levosimendan treatment in cardiac surgery: a network meta-analysis of randomized controlled trials. [PDF]

Front Cardiovasc Med
Zhu B, Zhao W, Li Y.
europepmc   +1 more source

In silico study of the mechanisms of hypoxia and contractile dysfunction during ischemia and reperfusion of hiPSC cardiomyocytes. [PDF]

Dis Model Mech
Forouzandehmehr M, Paci M, Hyttinen J, Koivumäki JT.   +3 more
europepmc   +1 more source

Improved survival with simendan after experimental myocardial infarction in rats [PDF]

European Journal of Pharmacology, 2001
This study compared the effects of simendan, a calcium sensitizer, with those of milrinone and enalapril on survival of rats with healed myocardial infarction. Seven days after ligation-induced myocardial infarction, the rats were randomized to control, milrinone, enalapril, or simendan groups. All compounds were administered via the drinking water for
Piero Pollesello, Heimo Haikala
exaly   +4 more sources

Enantiomeric analysis of simendan on polysaccharide‐based stationary phases by polar organic solvent chromatography [PDF]

Journal of Separation Science, 2020
AbstractHerein, the enantiomeric separation of simendan by high‐performance liquid chromatography with ultraviolet detection using polysaccharide‐based chiral stationary phases in polar organic mode is described. Three chiral columns (Chiralpak AD‐H, Chiralcel OD‐H, and Chiralpak AS) were screened using pure methanol and acetonitrile without additives ...
Yanxiong Ke
exaly   +4 more sources

Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers [PDF]

Clinical Pharmacology and Therapeutics, 1994
To assess pharmacokinetics and correlation of pharmacokinetics and pharmacodynamics of simendan, a new calcium-sensitizing compound aimed at the treatment of congestive heart failure, in healthy volunteers.Simendan was administered to eight healthy subjects in seven different doses, and its concentrations in plasma and proportions of enantiomers ...
Markku Nieminen, Saila Antila
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Hemodynamic effects of the novel cardiotonic drug simendan: Echocardiographic assessment in healthy volunteers

Cardiovascular Drugs and Therapy, 1994
Simendan is a novel cardiotonic drug with mixed properties, including calcium sensitization. Simendan was given intravenously to eight healthy volunteers in doses from 0.1 to 10.0 mg to define its safety and dose-response effects. Its effects on myocardial function were recorded by echocardiography with simultaneous measurement of heart rate (HR) and ...
Markku Nieminen, Nieminen Markku S
exaly   +3 more sources

Enantiomeric bioanalysis of simendan and levosimendan by chiral high-performance liquid chromatography

Chirality, 1996
rac-Simendan, (+/-)-(R,S)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-phenyl ] hydrazono]propanedinitrile, and the levorotatory enantiomer levosimendan, are drug candidates intended for the treatment of congestive heart failure. An enantiospecific high-performance liquid chromatographic (HPLC) method suitable for determination of the ratio of
T, Wikberg, T, Korkolainen, M, Karlsson
exaly   +3 more sources

Inotropic effect of simendan in combined hypoxia, hyperkalaemia and acidosis

Pharmacological Research, 1992
Julius Gy Papp
exaly   +2 more sources